enfortumab vedotin (EV)
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced or Metastatic Urothelial Carcinoma (UC)
Conditions
Locally Advanced or Metastatic Urothelial Carcinoma (UC)
Trial Timeline
— → —
NCT ID
NCT04136808About enfortumab vedotin (EV)
enfortumab vedotin (EV) is a pre-clinical stage product being developed by Astellas Pharma for Locally Advanced or Metastatic Urothelial Carcinoma (UC). The current trial status is completed. This product is registered under clinical trial identifier NCT04136808. Target conditions include Locally Advanced or Metastatic Urothelial Carcinoma (UC).
What happened to similar drugs?
5 of 20 similar drugs in Locally Advanced or Metastatic Urothelial Carcinoma (UC) were approved
Approved (5) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04136808 | Pre-clinical | Completed |
Competing Products
20 competing products in Locally Advanced or Metastatic Urothelial Carcinoma (UC)